(An Autonomous Body Recognized by Ministry of Commerce & Industry, Government of India)
AbbVie declares final analysis from Phase III trial of Elahere for ovarian cancer
AbbVie has released the final results of its Phase III MIRASOL trial, evaluating the efficacy and safety of Elahere, an antibody-drug conjugate (ADC), for treating platinum-resistant ovarian cancer (PROC). Elahere, which gained full FDA approval last year, was compared to standard chemotherapy in patients with folate receptor alpha (FRα) positive high-grade serous epithelial PROC.
The randomized trial included 453 participants and focused on progression-free survival (PFS) as the primary endpoint, while also assessing objective response rate (ORR) and overall survival (OS). The findings highlight Elahere’s potential as a more effective treatment option than chemotherapy for this aggressive cancer.
By specifically targeting FRα-positive cancer cells, Elahere may offer improved outcomes with fewer side effects compared to conventional chemotherapy. These results could pave the way for broader use of ADCs in ovarian cancer treatment, addressing the urgent need for better therapies in patients with limited options.
17-03-2025